Table 3.

In vitro antifungal susceptibilities of C. albicans strains from hemoculture^a,b.

Drug	MIC (μ/ml)				No. (%) of strains interpreted by CBPs				No. (%) of strains interpreted by ECVs
	Range	MIC50	MIC90	GM	S	SDD	I	R	WT	Non-WT
AFG	0.015–0.12	0.015	0.12	0.030	46 (100%)	N/A	0	0	46 (100%)	0
MFG	≤0.008–0.015	≤0.008	0.008	0.008	46 (100%)	N/A	0	0	46 (100%)	0
CFS	0.008–0.12	0.03	0.06	0.036	46 (100%)	N/A	0	0	N/A	N/A
AmB	0.25–0.5	0.5	0.5	0.381	N/A	N/A	N/A	N/A	46 (100%)	0
5-FC	≤0.06–0.25	≤0.06	0.06	0.065	N/A	N/A	N/A	N/A	N/A	N/A
PSO	0.015–≥ 8	0.015	0.03	0.020	N/A	N/A	N/A	N/A	N/A	N/A
VRC	≤0.008–≥ 8	0.008	0.015	0.010	45 (97.83%)	0	N/A	1 (2.17%)	N/A	N/A
ITC	0.03–≥ 16	0.06	0.06	0.052	N/A	N/A	N/A	N/A	N/A	N/A
FLU	0.12–16	0.25	1	0.398	45 (97.83%)	0	N/A	1 (2.17%)	N/A	N/A

^aN/A, not applicable; GM, geometric mean; CBP, clinical breakpoint; ECV, epidemiology cut-off value; S, susceptible; SDD, susceptible dose dependent; I, intermediate; R, resistant; WT, wild-type strain; AFG, anidulafungin; MFG, micafungin; CFG, caspofungin; AmB, amphotericin B; 5-FC, 5-flucytosine; PSO, posaconazole; VRC, voriconazole; ITC, itraconazole; FLU, fluconazolea. ^bInterpretation (CBP and ECV: ug/ml) of susceptibility testing were in accordance with the recommendation of the CLSI for C. albicans; CBPs: Anidulafungin, Micafungin and Caspofungin: S < 25, 1 = 0.5, R > 1; Voriconazole: S < 0.12, SDD = 0.25-0.5, R > 1; Fluconazole: S < 2, SDD = 4, R > 8; ECVs, Anidulafungin = 0.12; Micafungin = 0.03; Amphotericin B = 2.